Summary of findings 2. Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients.
| Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients | ||||||
| Patient or population: lung transplant recipients Settings: patients with end‐stage lung disease who underwent lung transplantation Intervention: polyclonal antibody Comparison: no antibody induction | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | Number of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| No antibody induction | Polyclonal antibody | |||||
| Mortality Follow‐up: 2 to 8 years | Study population | RR 1.02 (0.71 to 1.47) | 125 (3) | ⊕⊕⊕⊝ moderate¹ | ||
| 448 per 1000 | 457 per 1000 (318 to 659) | |||||
| Moderate | ||||||
| 400 per 1000 | 408 per 1000 (284 to 588) | |||||
| Acute rejection grade II or higher Follow‐up: 2 to 8 years | Study population | RR 0.68 (0.44 to 1.04) | 125 (3) | ⊕⊕⊕⊝ moderate¹ | ||
| 483 per 1000 | 328 per 1000 (212 to 502) | |||||
| Moderate | ||||||
| 500 per 1000 | 340 per 1000 (220 to 520) | |||||
| Infection Follow‐up: 2 to 8 years | Study population | RR 1.4 (0.97 to 2.01) | 104 (2) | ⊕⊕⊕⊝ moderate¹ | ||
| 458 per 1000 | 642 per 1000 (445 to 921) | |||||
| Moderate | ||||||
| 458 per 1000 | 641 per 1000 (444 to 921) | |||||
| Bronchiolitis obliterans syndrome Follow‐up: 2 to 8 years | Study population | RR 0.81 (0.57 to 1.16) | 125 (3) | ⊕⊕⊕⊝ moderate¹ | ||
| 534 per 1000 | 433 per 1000 (305 to 620) | |||||
| Moderate | ||||||
| 400 per 1000 | 324 per 1000 (228 to 464) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool